Hoth Therapeutics, Inc. announced t that it has received written approval from the University of Texas MD Anderson Cancer Center Institutional Review Board (IRB) to proceed with its First-in-Human (FIH) Phase 2a clinical trial of HT-001 for the treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi). This clinical trial is a randomized, placebo-controlled, parallel Phase 2a dose- ranging study to investigate the efficacy, safety, and tolerability of topical HT-001 for the treatment of skin toxicities associated with EGFRi. More information can be found at clinicaltrials.gov.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.93 USD | +2.20% |
|
-3.29% | -35.42% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.42% | 4.45M | |
+51.99% | 803B | |
-5.72% | 351B | |
+18.94% | 324B | |
+11.07% | 303B | |
+16.96% | 243B | |
+2.25% | 228B | |
+11.15% | 217B | |
+7.59% | 164B | |
-3.65% | 155B |
- Stock Market
- Equities
- HOTH Stock
- News Hoth Therapeutics, Inc.
- Hoth Therapeutics Announces Irb Approval for Fda Cleared First-In-Human Clinical Trial of Ht-001 At Second Clinical Site